Finally, elotuzumab is a moAb specifically directed against SLAMF7, a glycoprotein expressed on myeloma cells, able to promote the killing of myeloma cells, mainly through NK-mediated ADCC, as well as by preventing interactions between myeloma cells and BM stromal cells [121,122,123,124]. The gene discussed is SLAMF7; the disease is plasma cell myeloma.